Dieser Abschnitt ist nur in englischer Sprache verfügbar.

– Financial reporting – Consolidated balance sheet

Consolidated balance sheet

millions of CHF

 

Notes

 

June 30, 2022

 

December 31, 2021

 

June 30, 2021 1)

Non-current assets

 

 

 

 

 

 

 

 

Goodwill

 

 

 

702.5

 

727.3

 

1’022.4

Other intangible assets

 

 

 

253.0

 

276.5

 

461.1

Property, plant and equipment

 

 

 

381.8

 

394.0

 

565.8

Lease assets

 

 

 

77.8

 

89.2

 

131.5

Associates

 

 

 

24.2

 

25.5

 

26.8

Other non-current financial assets

 

 

 

15.1

 

18.0

 

14.7

Defined benefit assets

 

2

 

 

134.3

 

142.4

Non-current receivables

 

 

 

4.4

 

5.3

 

4.6

Deferred income tax assets

 

 

 

182.9

 

164.2

 

166.0

Total non-current assets

 

 

 

1’641.8

 

1’834.2

 

2’535.3

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Inventories

 

 

 

524.4

 

475.6

 

582.2

Current income tax receivables

 

 

 

27.2

 

26.7

 

28.1

Advance payments to suppliers

 

 

 

64.3

 

64.7

 

76.4

Contract assets

 

 

 

446.7

 

409.3

 

379.3

Trade accounts receivable

 

 

 

556.1

 

549.2

 

575.0

Other current receivables and prepaid expenses

 

 

 

142.6

 

118.7

 

134.6

Current financial assets

 

 

 

13.8

 

26.7

 

2.9

Cash and cash equivalents

 

 

 

1’300.6

 

1’505.4

 

1’292.5

Total current assets without disposal group

 

 

 

3’075.7

 

3’176.2

 

3’070.9

Assets of disposal group held for sale

 

7

 

42.4

 

 

Total current assets

 

 

 

3’118.2

 

3’176.2

 

3’070.9

Total assets

 

 

 

4’760.0

 

5’010.4

 

5’606.1

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

Share capital

 

 

 

0.3

 

0.3

 

0.3

Reserves

 

 

 

994.4

 

1’273.5

 

1’462.5

Equity attributable to shareholders of Sulzer Ltd

 

 

 

994.7

 

1’273.8

 

1’462.8

Non-controlling interests

 

 

 

4.1

 

5.5

 

6.4

Total equity

 

11

 

998.8

 

1’279.3

 

1’469.3

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

Non-current borrowings

 

12

 

1’164.7

 

1’164.6

 

1’489.6

Non-current lease liabilities

 

 

 

54.6

 

64.5

 

97.8

Deferred income tax liabilities

 

 

 

59.6

 

84.1

 

127.3

Non-current income tax liabilities

 

 

 

2.2

 

2.2

 

4.6

Defined benefit obligations

 

 

 

168.3

 

180.0

 

233.8

Non-current provisions

 

13

 

67.3

 

68.0

 

66.4

Other non-current liabilities

 

 

 

1.3

 

5.4

 

7.0

Total non-current liabilities

 

 

 

1’518.0

 

1’568.8

 

2’026.6

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Current borrowings

 

12

 

341.7

 

345.5

 

231.8

Current lease liabilities

 

 

 

22.8

 

24.3

 

33.0

Current income tax liabilities

 

 

 

26.1

 

40.2

 

11.1

Current provisions

 

13

 

158.7

 

167.8

 

184.1

Contract liabilities

 

 

 

364.5

 

324.5

 

346.4

Trade accounts payable

 

 

 

453.6

 

431.8

 

478.2

Other current and accrued liabilities

 

14

 

833.3

 

828.1

 

825.7

Total current liabilities without disposal group

 

 

 

2’200.7

 

2’162.3

 

2’110.2

Liabilities of disposal group held for sale

 

7

 

42.4

 

 

Total current liabilities

 

 

 

2’243.2

 

2’162.3

 

2’110.2

Total liabilities

 

 

 

3’761.1

 

3’731.1

 

4’136.9

 

 

 

 

 

 

 

 

 

Total equity and liabilities

 

 

 

4’760.0

 

5’010.4

 

5’606.1

Due to rounding, numbers presented may not add up to the totals provided.

1) The balance sheet as of June 30, 2021, includes the Applicator Systems division (later renamed medmix) classified as a discontinued operation. The spin-off was completed on September 20, 2021, (see note 6). Defined benefit assets were re-presented in the balance sheet as of June 30, 2021, defined benefit assets of CHF 142.4 million previously presented in other current receivables and prepaid expenses are presented in defined benefit assets. The balance sheet was also adjusted for measurement period adjustments related to the finalization of the purchase price accounting of acquisitions in 2020 (see note 4).